Modulation of Galectin-3 and Galectin 9 in gastric mucosa of patients with chronic gastritis and positive Helicobacter pylori infection

Estevam, Rayane Bernardes; Silva, Natália Maria Jacom Wood da; Silva, Wood da; Fonseca, Fernanda Machado; Oliveira, Adriana Gonçalves de; Nogueira,; Pereira, Sanívia Aparecida de Lima; Pereira, Thiago Lima; Adad, Sheila Jorge; Rodrigues, Virmondés; Rodrigues, Denise Bertulucci Rocha

doi:10.1016/j.prp.2017.08.005

Cited by 8 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression levels of galectins alter dramatically under various conditions, including pathogenic infections or disease progression [34]. Gal-3 expression in the stroma of the stomach is elevated following an H. pylori infection [35]. Therefore, we anticipated that the Gal-2 concentrations used in this study were within physiological limits.…”

Section: Discussionmentioning

confidence: 99%

Galectin-2 Has Bactericidal Effects against Helicobacter pylori in a β-galactoside-Dependent Manner

Sasaki

Saito

Oyama

et al. 2020

IJMS

View full text Add to dashboard Cite

Helicobacter pylori is associated with the onset of gastritis, peptic ulcers, and gastric cancer. Galectins are a family of β-galactoside-binding proteins involved in diverse biological phenomena. Galectin-2 (Gal-2), a member of the galectin family, is predominantly expressed in the gastrointestinal tract. Although some galectin family proteins are involved in immunoreaction, the role of Gal-2 against H. pylori infection remains unclear. In this study, the effects of Gal-2 on H. pylori morphology and survival were examined. Gal-2 induced H. pylori aggregation depending on β-galactoside and demonstrated a bactericidal effect. Immunohistochemical staining of the gastric tissue indicated that Gal-2 existed in the gastric mucus, as well as mucosa. These results suggested that Gal-2 plays a role in innate immunity against H. pylori infection in gastric mucus.

show abstract

Section: Discussionmentioning

confidence: 99%

Galectin-2 Has Bactericidal Effects against Helicobacter pylori in a β-galactoside-Dependent Manner

Sasaki

Saito

Oyama

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…The induction of other IC molecules in the context of H. pylori infection has also been reported. For example, a recent immunohistochemistry study found higher levels of Gal-3 in the gastric mucosa of patients with H. pylori infection, compared to noninfected subjects [124]. Finally, H. pylori stimulation resulted in a significant increase of Tim-3 in an in vitro system [125].…”

Section: Helicobacter Pylori Infection and Its Potential Relevancementioning

confidence: 99%

Gastric Cancer in the Era of Immune Checkpoint Blockade

Figueroa-Protti

Soto-Molinari

Calderón-Osorno

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most important malignancies worldwide because of its high incidence and mortality. The very low survival rates are mainly related to late diagnosis and limited treatment options. GC is the final clinical outcome of a stepwise process that starts with a chronic and sustained inflammatory reaction mounted in response to Helicobacter pylori infection. The bacterium modulates innate and adaptive immunity presumably as part of the strategies to survive, which favors the creation of an immunosuppressive microenvironment that ultimately facilitates GC progression. T-cell exhaustion, which is characterized by elevated expression of immune checkpoint (IC) proteins, is one of the most salient manifestations of immunosuppressive microenvironments. It has been consistently demonstrated that the tumor-immune microenvironment(TIME)‐exhausted phenotype can be reverted by blocking ICs with monoclonal antibodies. Although these therapies are associated with long-lasting response rates, only a subset of patients derive clinical benefit, which varies according to tumor site. The search for biomarkers to predict the response to IC inhibition is a matter of intense investigation as this may contribute to maximize disease control, reduce side effects, and minimize cost. The approval of pembrolizumab for its use in GC has rocketed immuno-oncology research in this cancer type. In this review, we summarize the current knowledge centered around the immune contexture and recent findings in connection with IC inhibition in GC.

show abstract

“…Gastritis is an inflammatory disease that is often associated with symptoms including stomach pain, bloating and anorexia. Chronic gastritis (CG) is characterized by mononuclear inflammatory cells, and has become a major disease that threatens human health (Estevam et al, 2017). Therefore, it is necessary to study the treatment of CG.…”

Section: Introductionmentioning

confidence: 99%

Comparative pharmacokinetics of four major flavonoids in normal and chronic gastritis rats after oral administration of different combinations of Banxia Xiexin decoction

Zhou

Liu

et al. 2022

Biomedical Chromatography

View full text Add to dashboard Cite

Chronic gastritis (CG) has become a major threat to human health. Banxia Xiexin Decoction (BXXXD) has been used clinically to treat gastritis by acting on the spleen and stomach for thousands of years. Baicalin, wogonoside, liquiritin and liquiritigenin are the main bioactive flavonoids of BXXXD. A rapid, sensitive and selective HPLCtriple quadrupole (TQ)-MS/MS method was developed to simultaneously quantify the four flavonoids in rat plasma in this study. With salidroside as internal standard (IS), plasma samples were extracted and separated on a Welch HPLC XB-C 18 column (2.1 Â 50 mm, 1.8 μm) using gradient elution. The optimized gradient of the mobile phase consisted of water (containing 0.1% formic acid) (A) and methanol (B) was used.Detection was implemented in multiple reaction monitoring mode with an electrospray negative ionization source. The comparative pharmacokinetics of four analytes in normal and CG rats after oral administration of BXXXD or its different compatibilities were first investigated. The results indicated that the pharmacokinetic behaviors of analytes were obviously changed in CG rats. From the comparison between the whole prescription group and the compatibility groups, it was found that the pharmacokinetic behavior of analytes also changed to some extent. The pharmacokinetic alterations of analytes might be due to the pathological conditions of CG.

show abstract

Modulation of Galectin-3 and Galectin 9 in gastric mucosa of patients with chronic gastritis and positive Helicobacter pylori infection

Cited by 8 publications

References 38 publications

Galectin-2 Has Bactericidal Effects against Helicobacter pylori in a β-galactoside-Dependent Manner

Galectin-2 Has Bactericidal Effects against Helicobacter pylori in a β-galactoside-Dependent Manner

Gastric Cancer in the Era of Immune Checkpoint Blockade

Comparative pharmacokinetics of four major flavonoids in normal and chronic gastritis rats after oral administration of different combinations of Banxia Xiexin decoction

Contact Info

Product

Resources

About